BioSpace News Archive

Caladrius Biosciences, Inc., announced that it has finalized an agreement to sell $10.9 million in New Jersey net operating losses to a qualifying and approved buyer pursuant to the New Jersey Economic Development Authority ’s Technology Business Tax Certificate Transfer Program.

AFYX Therapeutics (“AFYX”), a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced that its Rivelin ® Clobetasol patch (“Rivelin-CLO”) met the primary and multiple secondary endpoints in a Phase 2b study in patients with oral lichen planus (“OLP”). In t

Heska Corporation announced that it will expand its leadership team, adding a Chief Commercial Officer, a Chief Administrative Officer, and a Managing Director and Chief Operating Officer, scil animal care company, to its current Executive Leadership Team.

New German Territory Follows Accelerating Global Expansion with Orders in Singapore and Thailand This Month for Its Freezing Technology to Destroy Tumors

Ablexis, LLC , AlivaMab Discovery Services, LLC (“ADS”) and Berkeley Lights, Inc. today announced the rapid generation and recovery of sequences encoding a rich panel of human antibodies against the S1 spike protein of the S

Agilent Technologies Inc. (NYSE: A) announced today that it has become a top-level sponsor of My Green Lab , a nonprofit organization dedicated to improving the sustainability of scientific research. Run “for scientists, by scientists,” Agilent chose My Green Lab for their knowledge of the markets and scientific fields which both organizations

Imago BioSciences, Inc . (“Imago”), a clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that its Board of Directors has appointed a new independent director, Mr. Bob Baltera, Chief Executive Officer of Cirius Therapeutics. “Bob is a seasoned biotech executive who brings significant corporate development, business strategy and operational expertise to our

Dr. Poznansky will answer pre-submitted questions from investors at the conclusion of the call [22-April-2020] NEW YORK , April 22, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23, 2020 at 10:15 a.m. ET . Dr. Poznan

Silverback Therapeutics™ (“Silverback”) today announced that Laura Shawver, Ph.D., was appointed president, chief executive officer and director of Silverback Therapeutics to lead the next phase of growth utilizing ImmunoTAC™ therapeutics that are administered systemically, tissue-directed, and locally active with a pipeline of programs in oncology, fibrosis and virology. Dr. Shawver brings more than 25 years of demonstrated

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that The European Patent Office (EPO) has granted the Company a new patent for the composition of COM701 or backup antibodies for the treatment of cancer. EPO Patent No. 3295951 , titled “Anti-P